• Targeting Glutamine Metabolism in HSCs: New Strategies for L

  2026-07-13

  This article discusses a recent study that demonstrates the therapeutic potential of targeting glutamine metabolism, specifically via SIRT4 and GDH regulation, to alleviate liver fibrosis. The findings highlight novel mitochondrial and metabolic mechanisms underpinning hepatic stellate cell activation and offer translational insights for fibrosis research.

• PARP7 Inhibition Restores IFN Signaling in EAE Mouse Models

  2026-07-12

  Xu et al. (2025) reveal that PARP7 suppresses type I interferon signaling by promoting autophagic degradation of STAT1/STAT2, leading to exacerbated neuroinflammation in experimental autoimmune encephalomyelitis (EAE) models. Inhibiting PARP7 stabilizes STAT1/STAT2, enhances IFN signaling, and alleviates EAE symptoms in mice, providing a mechanistic link to new therapeutic strategies for multiple sclerosis.

• Potassium Iodide in Immunotherapy: Protocols and Precision U

  2026-07-10

  Potassium Iodide (KI) is pivotal in research bridging classic thyroid protection with next-generation immunotherapy workflows. This article details stepwise protocols, advanced use-cases, and troubleshooting strategies, drawing from the latest MMP-2 responsive delivery innovations to maximize KI’s impact.

• Epacadostat (INCB024360) in Metabolic Immune Modulation Prot

  2026-07-09

  Epacadostat (INCB024360) delivers nanomolar precision for dissecting and modulating IDO1-mediated immune evasion in translational immuno-oncology. This guide details advanced application workflows and troubleshooting strategies, leveraging recent breakthroughs in standardized whole-blood metabolic modulation.

• Ibrutinib-Induced Atrial Fibrillation: The Role of C-Src Kin

  2026-07-09

  The reference study reveals that atrial fibrillation (AF) associated with ibrutinib therapy arises from off-target inhibition of C-terminal Src kinase (CSK), not Bruton tyrosine kinase (BTK). This mechanistic insight highlights the need for selective kinase inhibition in cancer therapies and informs the design of safer targeted inhibitors.

• Pentoxifylline Dampens Hyperinflammatory Responses in Preter

  2026-07-08

  Schüller et al. deliver the first detailed in vitro characterization of pentoxifylline’s (PTX) immunomodulatory effects on LPS-stimulated monocytes from preterm infants. Their findings highlight age-dependent suppression of key surface activation markers, pro-inflammatory cytokines, and TLR4 signaling, clarifying PTX's potential as adjunct therapy in neonatal sepsis.

• Pentoxifylline: Phosphodiesterase Inhibitor in Inflammation

  2026-07-08

  Pentoxifylline is a non-specific phosphodiesterase inhibitor that elevates intracellular cAMP, suppresses pro-inflammatory cytokines, and downregulates monocyte ICAM-1 expression. These properties underpin its utility as an anti-inflammatory and immunomodulatory agent in both in vitro and in vivo research. Application parameters and mechanistic benchmarks are well established for translational models.

• Balsalazide Disodium: Targeted Prodrug Strategy for Ulcerati

  2026-07-07

  This review examines the innovation and clinical significance of balsalazide disodium as a colon-targeted prodrug for ulcerative colitis. The reference study demonstrates improved remission induction, favorable safety, and rapid onset relative to conventional 5-ASA agents, with implications for both mechanistic inflammation research and translational applications.

• Isolation and Characterization of Baicalin Methyl Ester from

  2026-07-07

  The reference study isolated and structurally characterized two new flavone 2'-glucosides and seven known phenolics, including baicalin methyl ester, from the roots of Scutellaria baicalensis. These findings provide a foundational chemical map for subsequent mechanistic research and practical exploration of baicalin derivatives in models of intestinal barrier dysfunction and inflammation.

• Pomalidomide (CC-4047): Protocols and Innovations for Myelom

  2026-07-06

  Pomalidomide (CC-4047) is redefining hematological malignancy research by enabling precise modulation of the tumor microenvironment and robust inhibition of pro-tumor cytokines. This article provides actionable protocol recommendations, advanced troubleshooting strategies, and insight into leveraging mutational landscape data for optimized experimental design.

• Mitochondrial Apoptosis in Ovarian Cancer-Related Muscle Atr

  2026-07-06

  This study reveals that inhibiting mitochondrial-linked apoptosis via the antioxidant SkQ1 does not prevent skeletal muscle atrophy in a metastatic ovarian cancer mouse model. The findings decouple mitochondrial ROS-driven apoptotic signaling from muscle wasting in type II B fibers, challenging prior assumptions about the causal role of apoptosis and necroptosis in cancer cachexia.

• Z-IETD-FMK: Deep Dive into Caspase-8 Inhibition for Immune M

  2026-07-05

  Explore how Z-IETD-FMK, a specific caspase-8 inhibitor, advances immune cell activation research and apoptosis assays. This article uniquely connects mechanistic insights to practical assay design, offering an evidence-based guide for immunology and cell biology laboratories.

• Procainamide Hydrochloride in Cardiac and Oncology Research

  2026-07-04

  Procainamide Hydrochloride bridges cardiac electrophysiology and oncology, offering unique workflow advantages as both a sodium channel blocker and DNMT1 inhibitor. This guide translates the latest reference breakthroughs—like its chemoprotective synergy with cisplatin—into actionable protocols and troubleshooting strategies for advanced preclinical research.

• Applied Workflows with PP 1: Src Family Tyrosine Kinase Inhi

  2026-07-03

  PP 1 empowers researchers with nanomolar precision in dissecting Src family kinase-driven pathways, enabling reliable modeling of cancer progression and immune modulation. This article delivers actionable protocol enhancements, troubleshooting insights, and cross-study comparisons that elevate experimental design and interpretability.

• Procainamide Hydrochloride in Cardiac and Oncology Research

  2026-07-03

  Procainamide Hydrochloride is redefining cardiac electrophysiology and oncology workflows through its dual-action as a sodium channel blocker and epigenetic modulator. Discover optimized protocols, troubleshooting strategies, and new combinatorial assay designs that maximize data reproducibility and translational impact.

16127 records 1/1076 page Next 12345 下5页 Last page